Trial reportSleep & breathing = Schlaf & Atmung2025
Effects of remotely-delivered cognitive behavioral therapy for insomnia in type 2 diabetes: a randomized controlled trial.
Trial report in Sleep & breathing = Schlaf & Atmung, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Insomnia as an Independent Behavioral Correlate of Estimated Type 2 Diabetes Risk: Evidence from Three Validated Risk Assessment Scales.Rambam Maimonides medical journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the effects of remotely delivered cognitive behavioral therapy for insomnia (CBTI) on subjective sleep quality, glycemic control, and objective sleep parameters in individuals with type 2 diabetes (T2D) and insomnia.
methodsForty adults with non-insulin-treated T2D and insomnia were randomized to CBTI (n = 20) or health education (HE, n = 20), delivered weekly via one-hour online sessions for eight weeks. The primary outcome was self-reported sleep quality (Pittsburgh Sleep Quality Index, PSQI). Secondary outcomes included actigraphy-based sleep measures, glycemic control (A1C, fasting glucose), insomnia symptoms, anxiety, depression, and quality of Life. Data were collected at baseline, week 8, and week 16. Mixed-effects linear regression was used to assess between-group differences.
resultsAt week 8, no significant difference in PSQI was observed between groups, but the CBTI group showed improved actigraphy-based sleep regularity (variation of sleep duration), mean difference - 21.84 min (95% CI -41.64, -2.05; P = 0.031). At week 16, CBTI led to a greater reduction in anxiety symptoms (P = 0.039). There were no differences in other outcomes. In per-protocol analysis (CBTI: n = 15; HE: n = 10), CBTI resulted in improved subjective sleep quality (P = 0.042), sleep regularity (P = 0.018) and fasting glucose at week 8 (mean difference - 34.27 mg/dL; 95% CI -55.16, -13.37; P = 0.001). Satisfaction was high in both groups.
conclusionCBTI improved sleep regularity and anxiety in T2D patients with insomnia. Adherence to CBTI also led to fasting glucose reductions, supporting its role in glycemic management. Sleep-focused interventions like CBTI should be integrated into care for T2D with insomnia to optimize sleep and metabolic outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.